Thymalin

Thymalin is not a single molecule but a fraction of low-molecular-weight polypeptides extracted from calf thymus, developed in the Soviet military-medical programme and later commercialised by Khavinson's group. It acts as a substitute for the thymic hormone signalling that fades as the thymus involutes after adolescence, promoting differentiation of T-cell precursors and normalising CD4/CD8 ratios and natural killer cell activity in aged or immunosuppressed subjects. Reported downstream effects include normalisation of interleukin production and improved response to infection. Because it is an extract rather than a defined peptide, batch-to-batch composition is inherently variable, and no one can point to a single receptor or pathway with confidence — the evidence is functional and clinical rather than molecular.

Targets: T-lymphocyte differentiation, CD4/CD8 ratio, Natural killer cell activity, Interleukin-2 signalling

• · 10 mg per day for 5-10 days, repeated every six months. This is the dose used in the Russian clinical literature, not a community extrapolation.
• · Run on synchronised courses with Epitalon in the elderly cohorts that produced the mortality data.

Work out your exact syringe units →

• commonInjection-site pain or induration— More noticeable intramuscularly than subcutaneously.
• uncommonTransient low-grade fever or malaise— Consistent with immune activation; usually first two days of a course.
• rareAllergic reaction to bovine protein— This is an animal-derived extract — a real, if uncommon, hypersensitivity risk that defined synthetic peptides do not carry.

• Known allergy to bovine proteins.
• Active autoimmune disease — stimulating T-cell function in someone whose T-cells are already attacking them is not obviously wise.
• Solid organ transplant on immunosuppression — directly counter to the therapeutic goal.
• Pregnancy and breastfeeding — no data.

• synergyepitalon — The canonical Khavinson pairing; the two were administered together in the long-term elderly cohorts.
• redundantthymosin-alpha-1 — Thymosin alpha-1 is a defined synthetic thymic peptide covering similar ground with far better characterisation — most people should pick one.
• conflictimmunosuppressants — Opposing pharmacology; do not stack with ciclosporin, tacrolimus or similar.

• · CBC with differential before and after a course if you want an objective read.
• · Lymphocyte subsets (CD4, CD8, NK) if accessible — these are the markers the original studies moved.
• · Frequency of infections over the following six months is the practical endpoint.

Registered as a medicine in Russia; not approved in the US or EU, where it is sold as a research chemical.

• Khavinson & Morozov 2003, Neuroendocrinology Letters — long-term follow-up of Thymalin and Epithalamin in elderly patients (trial)
• Khavinson, review of peptide bioregulators and immune ageing (review)

Thymalin is best understood as thymic hormone replacement for a gland that has largely disappeared. The thymus involutes from adolescence onward, and with it goes the signalling environment that drives T-cell precursors through differentiation. Thymalin supplies a mixture of thymic polypeptides that substitute for part of that signalling, and the observable consequences in the Russian clinical literature are normalised CD4/CD8 ratios, restored natural killer cell activity, and normalised interleukin production in aged or immunosuppressed subjects. The mechanistic work that exists is mostly recent and mostly from the Khavinson group itself. A 2020 Bulletin of Experimental Biology and Medicine paper reported that Thymalin acting on cultured human haematopoietic stem cells reduced CD44 and CD117 expression two to threefold while increasing CD28 by 6.8-fold — that is a differentiation signal, pushing progenitors toward mature T lymphocytes rather than simply stimulating existing ones. A 2023 IJMS paper went further and attributed the anti-inflammatory activity specifically to the KE and EW dipeptides, reporting reductions of 1.4 to 6.0-fold in IL-1beta, IL-6 and TNF-alpha synthesis in stimulated human peripheral blood mononuclear cells. That is the closest anyone has come to naming a molecular basis. The structural honesty here is important: because Thymalin is an extract, no one can point to a receptor and no one can guarantee that this batch contains what the last batch contained. The evidence is functional and clinical rather than molecular, and clinical evidence for a chemically undefined product is very hard to independently verify — which is precisely why nothing outside Russia has replicated it.

The first thing is the one nobody expects: this is a bovine tissue extract. Every other compound on this page is a synthetic molecule; Thymalin is a fraction of calf thymus. That means a real hypersensitivity risk to bovine protein, and it means genuine batch-to-batch variation in what you are injecting, which no amount of vendor testing fixes because there is no defined analyte to test for. The second is autoimmunity. People buy this as a longevity item and never consider that stimulating T-cell differentiation in someone with Hashimoto's, rheumatoid arthritis or psoriatic disease is pushing on exactly the wrong lever. If you have an autoimmune condition, this is a genuine contraindication rather than a cautious one. The third is running it continuously. The clinical protocol is 5-10 days, twice a year, and unusually for this field that cycling pattern comes from the actual studies rather than from forum convention — so ignoring it means departing from the only evidence the compound has. The fourth is solution handling: extracts are less predictable in solution than defined peptides, and the sensible practice is to reconstitute daily or at most every few days during a course rather than holding a vial of solution for weeks. The fifth is expecting to feel something. You will not, beyond possibly some low-grade malaise in the first two days from immune activation. The endpoints here are markers and infection frequency, not sensation.

• T-lymphocyte precursor differentiation — No receptor identified; Thymalin is a mixture and no ligand-receptor pair has been defined.

  Drives differentiation of haematopoietic progenitors toward mature T cells — CD44 and CD117 down two to threefold, CD28 up 6.8-fold in cultured human stem cells.

• CD4/CD8 ratio — Not applicable.

  Normalisation toward age-appropriate values in aged and immunosuppressed subjects. This is the marker the original clinical work leaned on most heavily.

• Natural killer cell activity — Not applicable.

  Restoration of NK cytotoxic function reported in the Russian clinical literature.

• IL-1beta, IL-6 and TNF-alpha synthesis (via the KE and EW dipeptide components) — Not characterised as a binding interaction.

  Reduced pro-inflammatory cytokine synthesis by 1.4 to 6.0-fold in LPS-stimulated human peripheral blood mononuclear cells. This is the most specific molecular result the preparation has.

• Khavinson & Morozov long-term geroprotection cohort (Thymalin and Epithalamin in elderly subjects) Open-label controlled clinical study · n=266 · 416 weeks · 2003

  All-cause mortality over 6-8 years. Reported a 2.0-2.1-fold reduction with Thymalin alone, 1.6-1.8-fold with Epithalamin alone, 2.5-fold with the combination, and a 4.1-fold reduction in the subgroup treated with the combination annually over six years. This is the strongest human dataset for any compound in this class and it is also open-label, single-country and unreplicated.

• Thymalin in complex therapy for severe COVID-19 in older patients Clinical study (controlled, not blinded) · 2021

  Immune status and inflammatory markers. Adding Thymalin to standard therapy accelerated the decline in IL-6 and C-reactive protein and in T-cell system indicators compared with the control group. Participant numbers and randomisation details were not resolvable from the abstract in this session.

Days one to two of a course: occasionally transient low-grade fever or malaise, consistent with immune activation. Days three to ten: the course completes; immune-marker changes were reported as developing across this window in the Russian work. Weeks two to four after the course: this is when lymphocyte subset changes should be measurable, and the right time to draw the follow-up panel. Months one to six: the claimed persistence window, which is why courses are spaced six months apart. Years: the mortality signal in the 266-subject cohort emerged over 6-8 years of repeated annual courses, and that is the timescale of the actual claim.

Thymalin plus Epitalon on synchronised courses is the canonical pairing and it is the only stack in this class with human outcome data behind it — the 2.5-fold and 4.1-fold mortality figures came from the combination, not from either alone. If you are running Khavinson bioregulators at all, this is the version that matches the protocol that produced the data. Thymalin and thymosin alpha-1 overlap heavily: thymosin alpha-1 is a defined 28-residue synthetic peptide with real characterisation, an actual approval in several countries, and no bovine protein in it. On every axis except cost and tradition, thymosin alpha-1 is the better-specified choice, and most people should pick one rather than run both. The genuine conflict is with immunosuppression — ciclosporin, tacrolimus, mycophenolate, high-dose corticosteroids, and biologics for autoimmune disease all exist to do the opposite of what Thymalin is for. Do not stack them. If you have had a solid organ transplant, this compound is directly counter-therapeutic. Buying the KE and EW dipeptides separately (Vilon and Thymogen) is a way to get defined molecules instead of an extract, which solves the batch-variability problem, at the cost of losing whatever else is in the extract that might matter.

Against Epitalon: Thymalin is the stronger of the two Khavinson compounds. It moves markers you can actually order from a normal laboratory, its mortality signal in the cohort was larger, and its mechanism carries no theoretical cancer hazard — if anything, restoring immune surveillance argues the other way. If you are picking one bioregulator, pick this one. Against thymosin alpha-1: thymosin alpha-1 wins on chemistry, characterisation and regulatory status, and it is a defined synthetic peptide rather than an animal extract. It has been approved and used clinically for hepatitis B and as an immune adjunct in several countries. The only arguments for Thymalin over it are cost, tradition, and the fact that the long-term mortality cohort used Thymalin specifically. Against doing nothing: for an older adult with documented low lymphocyte counts and frequent infections, Thymalin has more human evidence behind it than almost anything else discussed on this site — while remaining open-label, single-country and unreplicated, which is a real and permanent asterisk. Against modern immune interventions: nothing in the Thymalin literature meets the evidentiary standard of a contemporary randomised trial, and it should not be described as though it does.

$25–$90/month. Not verified against live pricing this session. A standard course is 50-100 mg total (10 mg daily for 5-10 days) and Thymalin is inexpensive by peptide standards. Because the protocol is two courses a year, the honest figure is roughly 50 to 200 USD annually rather than a monthly cost. Russian-registered pharmaceutical Thymalin and grey-market research-grade product differ substantially in price and in what assurance you get about the contents.

• ?No pharmacokinetic profile exists and none is definable for an undefined mixture.
• ?The composition of Thymalin is not standardised in any published way I could verify, so batch equivalence cannot be assumed.
• ?The 266-subject mortality cohort was open-label; I could not access the full methods to determine how controls were selected or whether randomisation occurred.
• ?The mortality reductions have never been replicated outside Russia, and the compound has never been tested in a modern blinded randomised trial.
• ?Participant numbers and design details for the COVID-19 clinical work were not resolvable from the abstracts available in this session.
• ?The KE/EW cytokine result was in cells from only four donors, which is a very small mechanistic study to carry as much weight as it does.
• ?Whether the identified KE and EW dipeptides account for all, most or a small part of the preparation's activity is unknown.
• ?Whether Thymalin crosses the blood-brain barrier is unknown and probably not meaningful for an undefined mixture.
• ?Cost figures are estimates and were not verified against live vendor pricing.
• ?The relative merits of intramuscular versus subcutaneous administration have not been formally compared; the original Russian protocol is intramuscular.

• Peptides of pineal gland and thymus prolong human life Khavinson VKh, Morozov VG, Neuroendocrinology Letters, 2003 · PMID 14523363

  The 266-subject, 6-8 year mortality cohort. Every claim made for Thymalin as a geroprotector rests on this and its companion paper. Open-label, unreplicated outside Russia, and still the best human data in this entire class.

• Geroprotective effect of thymalin and epithalamin Khavinson VKh, Morozov VG, Advances in Gerontology, 2002 · PMID 12577695

  The companion publication of the same cohort, reporting the same mortality reductions. Worth knowing these are the same 266 subjects and not two independent datasets.

• Thymalin: activation of differentiation of human hematopoietic stem cells Khavinson VK, Linkova NS, Kvetnoy IM, et al., Bulletin of Experimental Biology and Medicine, 2020 · PMID 33237528

  The mechanistic result — CD44 and CD117 down two to threefold, CD28 up 6.8-fold in cultured human haematopoietic stem cells. Evidence that Thymalin drives differentiation rather than simply stimulating existing lymphocytes.

• Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-19 Khavinson VK, Kuznik BI, Tarnovskaya SI, et al., Stem Cell Reviews and Reports, 2021 · PMID 33575961

  The most recent clinical application — Thymalin added to standard COVID-19 therapy accelerated the fall in IL-6 and CRP and improved T-cell indicators versus control. Notable because it is a modern, acute-illness setting rather than a long geroprotection cohort.

• The influence of KE and EW dipeptides in the composition of the Thymalin drug on gene expression and protein synthesis involved in the pathogenesis of COVID-19 Linkova N, Khavinson V, Diatlova A, et al., International Journal of Molecular Sciences, 2023 · PMID 37686182

  Names the active components. KE and EW dipeptides reduced IL-1beta, IL-6 and TNF-alpha synthesis by 1.4 to 6.0-fold in human peripheral blood mononuclear cells. This is the closest thing to a defined molecular basis Thymalin has — and note it was only four donors.